sulfasalazine has been researched along with Angiogenesis, Pathologic in 4 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| " TL-118, a novel drug combination has been recently developed to inhibit tumor angiogenesis." | 5.40 | TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI. ( Abramovitch, R; Corchia, N; Dery, E; Fried, I; Gross, E; Komar-Stossel, C; Meir, K, 2014) |
| " TL-118, a novel drug combination has been recently developed to inhibit tumor angiogenesis." | 1.40 | TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI. ( Abramovitch, R; Corchia, N; Dery, E; Fried, I; Gross, E; Komar-Stossel, C; Meir, K, 2014) |
| "We present a first description of a pancreatic cancer patient treated with standard chemotherapy and TL-118, an anti-angiogenic combination of 4 drugs that target non-overlapping aspects of the angiogenic process (Provided by Tiltan Pharma Ltd for compassionate use)." | 1.39 | TL-118-anti-angiogenic treatment in pancreatic cancer: a case report. ( Appelbaum, L; Breuer, S; Hubert, A; Maimon, O; Peretz, T, 2013) |
| "Esophageal cancer is the eighth most common malignancy, and one of the leading causes of cancer-related deaths worldwide." | 1.35 | Targeting NF-kappaB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer. ( Cheung, AL; Li, B; Li, YY; Tsao, SW, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Breuer, S | 1 |
| Maimon, O | 1 |
| Appelbaum, L | 1 |
| Peretz, T | 1 |
| Hubert, A | 1 |
| Komar-Stossel, C | 1 |
| Gross, E | 1 |
| Dery, E | 1 |
| Corchia, N | 1 |
| Meir, K | 1 |
| Fried, I | 1 |
| Abramovitch, R | 1 |
| Li, B | 1 |
| Li, YY | 1 |
| Tsao, SW | 1 |
| Cheung, AL | 1 |
| Madhok, R | 1 |
| Wijelath, E | 1 |
| Smith, J | 1 |
| Watson, J | 1 |
| Sturrock, RD | 1 |
| Capell, HA | 1 |
4 other studies available for sulfasalazine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
TL-118-anti-angiogenic treatment in pancreatic cancer: a case report.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Cyclophos | 2013 |
TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Prolifera | 2014 |
Targeting NF-kappaB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer.
Topics: Animals; Esophageal Neoplasms; Female; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice | 2009 |
Is the beneficial effect of sulfasalazine due to inhibition of synovial neovascularization?
Topics: Aminosalicylic Acids; Arthritis, Rheumatoid; Cell Division; Endothelium, Vascular; Humans; Mesalamin | 1991 |